Lefty inhibitors belong to a distinct class of chemical compounds known for their pivotal role in regulating embryonic development and cell differentiation. These inhibitors are closely associated with the transforming growth factor-beta (TGF-β) superfamily of signaling molecules. To understand Lefty inhibitors, it's essential to appreciate their role within the intricate process of embryogenesis. During early development, Lefty inhibitors play a fundamental role in establishing the body plan of an organism. They are known for their function in maintaining symmetry and axis formation, a critical step in the early stages of embryonic development. Lefty inhibitors act as antagonists to certain signaling pathways within the TGF-β superfamily, exerting their influence by interfering with the signaling molecules involved. Specifically, they counteract the activity of Nodal, an important TGF-β member, which plays a key role in specifying the left-right axis in vertebrates. By doing so, Lefty inhibitors help ensure that the developing embryo forms with appropriate bilateral symmetry, preventing developmental abnormalities and ensuring the proper organization of vital organs.
Lefty inhibitors can be broadly classified into two isoforms: Lefty-1 and Lefty-2. Both isoforms exhibit similar mechanisms of action, working as negative regulators by binding to Nodal and inhibiting its signaling. This function is crucial for maintaining the balance of the Nodal pathway, preventing excessive or inappropriate signaling that could lead to developmental defects. Lefty inhibitors are a prime example of the delicate checks and balances that govern embryonic development. Their presence ensures the precise orchestration of signaling pathways, guaranteeing that an organism's body plan and symmetry are established correctly during its early stages of development. Understanding the mechanisms of Lefty inhibitors is not only essential for developmental biology but also holds potential implications for various fields of science and medicine, shedding light on the intricacies of cell signaling and differentiation.
VOIR ÉGALEMENT...
Items 11 to 15 of 15 total
Afficher:
| Nom du produit | CAS # | Ref. Catalogue | Quantité | Prix HT | CITATIONS | Classement |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Le lapatinib est un double inhibiteur de l'EGFR et de HER2 qui inhibe les tyrosines kinases, entravant ainsi la croissance et la propagation des cellules mammaires HER2-positives. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Le vémurafénib inhibe spécifiquement les mutations BRAF V600E, stoppant la prolifération incontrôlée des cellules de mélanome présentant cette mutation spécifique. | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
Le régorafénib est un inhibiteur multikinase qui cible les récepteurs angiogéniques, les kinases stromales et les kinases oncogéniques, ce qui permet de contrôler la croissance et l'angiogenèse. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
L'osimertinib est un inhibiteur de tyrosine kinase de l'EGFR conçu pour cibler les mutations T790M de l'EGFR et vaincre la résistance chez les patients atteints de cancer du poumon non à petites cellules (CBNPC). | ||||||
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | 1032900-25-6 | sc-505041 | 1 mg | $230.00 | ||
Le céritinib inhibe les kinases ALK et ROS1, spécifiquement étudiées dans la recherche de cellules non à petites cellules (NSCLC) présentant des réarrangements des gènes ALK ou ROS1, bloquant ainsi la croissance tumorale. | ||||||